ICT-01

点击蓝字关注我们编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。作为全球规模最大、学术水平最高、最具权威性的国际肿瘤会议之一，2025年ASCO年会将汇聚顶级肿瘤专家、学者和行业领袖，共探肿瘤领域的前沿研究成果和先进治疗方法。日前，2025 ASCO入选摘要标题（包括Late-Breaking Abstracts）已发布。摘要具体内容将在2025年5月22日发布，Late-breaking摘要内容将在会议当天发布。《肿瘤瞭望-血液时讯》特别整理血液肿瘤领域的重磅研究，包括1项LBA、27项口头报告、27项快速口头报告，助力大家提前了解会议的重磅内容。01Plenary Session当地时间：6月1日13:00-16:00报告地点：Hall B1摘要号：LBA3英文标题：Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV)中文标题：：rusfertide治疗真性红细胞增多症（PV）的三期、双盲、安慰剂（PBO）对照VERIFY研究结果讲者：Andrew Tucker Kuykendall, MD| Moffitt Cancer Center02Oral Abstract Session淋巴瘤与慢性淋巴细胞白血病当地时间：5月30日14:45–17:45报告地点：S100a摘要号：7000英文标题：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial中文标题：通过PhasED-Seq对国家试验中DLBCL患者治疗结束ctDNA MRD的前瞻性验证讲者：Steven Wang, MD | Amsterdam UMC Location Vrije Universiteit摘要号：7001英文标题：Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group中文标题：自然杀伤性 T 细胞淋巴瘤分期系统修订：中国西南肿瘤学组及亚洲淋巴瘤研究组多中心研究讲者：林桐榆（四川省肿瘤医院）摘要号：7002英文标题：Molecular landscape of distinct follicular lymphoma histologic grades: Insights from genomic and transcriptome analyses中文标题：不同组织学分级滤泡性淋巴瘤的分子图谱：来自基因组和转录组分析的见解讲者：孙聪（天津医科大学肿瘤医院）摘要号：7003英文标题：A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL)中文标题：KITE-363抗CD19/CD20嵌合抗原受体（CAR）T细胞治疗复发/难治性B细胞淋巴瘤患者的Ⅰ期临床研究讲者：Saurabh Dahiya, MD, FACP | Stanford University School of Medicine摘要号：7004英文标题：Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma中文标题：多病毒特异性T细胞用于增强双特异性抗体在淋巴瘤中的治疗活性讲者：Akiva Diamond, MD | Department of Medicine, Section of Hematology-Oncology, Baylor College of Medicine; Baylor St.Luke’s Medical Center; Dan L Duncan Comprehensive Cancer Center摘要号：7005英文标题：WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma中文标题：WaveLINE-003：zilovertamab vedotin联合标准治疗用于复发/难治性弥漫大B细胞淋巴瘤的Ⅱ/Ⅲ期临床试验讲者：Philippe Armand, MD, PhD | Dana-Farber Cancer Institute摘要号：7006英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)中文标题：信迪利单抗（抗PD-1抗体）联合西达本胺（一种口服HDACi）继以 P-GemOx 方案治疗初治结外自然杀伤性 /T 细胞淋巴瘤（TN-ENKTL）患者的多中心、开放标签、单臂、II 期研究（SCENT-2 试验）讲者：黄慧强（中山大学肿瘤防治中心）摘要号：7007英文标题：Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21)中文标题：信迪利单抗（抗PD-1）联合依托泊苷（ICE）方案用于二线治疗经典霍奇金淋巴瘤（cHL）：一项多中心、随机、对照、双盲 III 期研究（ORIENT-21）的结果讲者：刘鹏（中国医学科学院肿瘤医院）摘要号：7008英文标题：Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203)中文标题：先天细胞接合剂acimtamig（AFM13）联合AlloNK（AB-101）治疗复发或难治性经典型霍奇金淋巴瘤的Ⅱ期临床试验剂量探索部分结果（LuminICE-203）讲者：Joseph E. Maakaron, MD | Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：6月2日15:00-18:00报告地点：S100a摘要号：6500英文标题：Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial中文标题：Ropeginterferon alfa-2b vs. anagrelide治疗原发性血小板增多症：SURPASS-ET Ⅲ期临床试验的主要结果讲者：Ruben A. Mesa, MD | Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine摘要号：6501英文标题：Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)中文标题：asciminib（ASC）vs. nilotinib（NIL）用于新诊断慢性期慢性粒细胞白血病（CML-CP）患者的不良事件导致治疗中断时间（TTDAE）:ASC4START Ⅲb期临床试验主要终点结果讲者：Andreas Hochhaus, MD | Klinik für Innere Medizin II, Universitätsklinikum Jena摘要号：6502英文标题：Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study中文标题：CADENZA研究中pivekimab sunirine（PVEK）治疗母细胞性浆细胞样树突状细胞肿瘤（BPDCN）患者的疗效与安全性讲者：Naveen Pemmaraju, MD | The University of Texas MD Anderson Cancer Center摘要号：6503英文标题：Phase II study of cladribine, low-dose cytarabine, and venetoclax, alternating with azacitidine and venetoclax, in higher-risk chronic myelomonocytic leukemia and myelodysplastic syndromes中文标题：克拉屈滨、低剂量阿糖胞苷联合维奈克拉与阿扎胞苷联合维奈克拉交替治疗高危慢性粒单核细胞白血病和骨髓增生异常综合征的Ⅱ期临床研究讲者：Guillermo Montalban-Bravo, MD | The University of Texas MD Anderson Cancer Center摘要号：6504英文标题：An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts中文标题：全口服方案decitabine-cedazuridine（DEC-C）联合维奈克拉（VEN）用于不适合强化诱导化疗的新诊断急性髓系白血病（AML）患者：来自101例患者的Ⅱ期队列研究结果讲者：Amer Methqal Zeidan, MBBS | Yale University School of Medicine摘要号：6505英文标题：Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies中文标题：lisaftoclax（APG-2575）联合阿扎胞苷（AZA）治疗初治或既往接受过维奈克拉（VEN）治疗的髓系恶性肿瘤患者的Ⅰb/Ⅱ期临床研究讲者：Michael Francis Leahy, FRACP, FRCP, FRCPath, MBChB | Royal Perth Hospital摘要号：6506英文标题：Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study中文标题：Ziftomenib治疗复发/难治性（R/R）NPM1突变急性髓系白血病（AML）：关键KOMET-001研究中Ⅰb/Ⅱ期临床疗效和安全性结果讲者：Eunice S. Wang, MD | Roswell Park Comprehensive Cancer Center摘要号：6507英文标题：γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study EVICTION中文标题：γ9δ2 T细胞激活（γδTCA）联合ICT01和阿扎胞苷-维奈克拉（AV）治疗高龄/unfit新诊断急性髓系白血病（AML）成年患者：EVICTION Ⅰ/Ⅱ期研究中的初步疗效和剂量选择讲者：Pierre Yves Dumas, MD, PhD| CHU摘要号：6508英文标题：Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation中文标题：接受异基因造血干细胞移植后存活超过2年患者的长期结局讲者：Arjun Datt Law, MD, DM, MBBS, FCRP | Princess Margaret Cancer Centre浆细胞病当地时间：6月3日09:45-12:45报告地点：S100bc摘要号：7500英文标题：MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial中文标题：在适合移植的新诊断多发性骨髓瘤（NDMM）患者中，IsaKRD诱导后MRD驱动策略：MIDAS Ⅲ期临床试验的主要终点讲者：Aurore Perrot, MD, PhD | Toulouse University, CHU Oncopole摘要号：7501英文标题：Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial中文标题：皮下注射达雷妥尤单抗（Dara）+硼替佐米/来那度胺/地塞米松（VRd）联合达雷妥尤单抗+来那度胺（DR）维持治疗适合移植（TE）新诊断多发性骨髓瘤（NDMM）患者：PERSEUS Ⅲ期临床试验中持续微小残留病（MRD）阴性的分析讲者：Philippe Moreau, MD, PhD | University Hospital Hôtel-Dieu摘要号：7502英文标题：Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)中文标题：卡非佐米-来那度胺-地塞米松联合或不联合艾沙妥昔单抗（Isatuximab）治疗新诊断多发性骨髓瘤患者：Ⅲ期IsKia临床试验中的持续微小残留病（MRD）阴性分析讲者：Francesca Gay, MD, PhD | Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino摘要号：7503英文标题：Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial中文标题：卡非佐米、来那度胺和地塞米松（KRd）联合或不联合达雷妥尤单抗（D）治疗新诊断多发性骨髓瘤（NDMM）患者的随机多中心研究：ADVANCE临床试验讲者：Carl Ola Landgren, MD, PhD | Myeloma Program and Experimental Therapeutics Program, University of Miami摘要号：7504英文标题：Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1中文标题：Elranatamab联合达雷妥尤单抗和来那度胺（EDR）治疗不适合接受移植的新诊断多发性骨髓瘤（NDMM）患者：MagnetisMM-6 part 1的初步结果讲者：HANG QUACH, MD, FRACP, FRCPA | St Vincent’s Hospital Melbourne, University of Melbourne摘要号：7505英文标题：First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results中文标题：JNJ-79635322（JNJ-5322）新型三特异性抗体（TsAb）在复发/难治性多发性骨髓瘤（RRMM）患者中的首次人体研究：初步Ⅰ期结果讲者：Niels W.C.J. van de Donk, MD, PhD | Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology摘要号：7506英文标题：Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study中文标题：艾沙妥昔单抗（Isa）通过体外输送系统（OBDS）皮下（SC）给药vs. Isa静脉注射（IV），联合泊马度胺和地塞米松（Pd）治疗复发/难治性多发性骨髓瘤（RRMM）：随机非劣效性Ⅲ期IRAKLIA研究结果讲者：Xavier P. Leleu, MD, PhD | Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402摘要号：7507英文标题：Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)中文标题：CARTITUDE-1研究中接受ciltacabtagene autoleucel（cilta-cel）治疗的复发/难治性多发性骨髓瘤（RRMM）患者的长期（≥5年）缓解与生存情况讲者：Peter M. Voorhees, MD | Atrium Health / Levine Cancer Institute, Wake Forest University School of Medicine摘要号：7508英文标题：Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201中文标题：Nexicart-2的安全性与疗效数据：CAR-T在R/R轻链淀粉样变中的首次美国试验（Nxc-201）讲者：Heather Jolie Landau, MD | Memorial Sloan Kettering Cancer Center03Rapid Oral Abstract Session白血病、骨髓增生异常综合征与异基因造血干细胞移植当地时间：5月30日13:00-14:30报告地点：E450a摘要号：6509英文标题：A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults中文标题：asciminib联合达沙替尼、泼尼松和贝林妥欧单抗治疗成人Ph阳性急性白血病的Ⅰ期临床研究讲者：Marlise R Luskin, MD | Dana-Farber Cancer Institute摘要号：6510英文标题：MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis中文标题：PhALLCON Ⅲ期临床试验中诱导治疗结束后的MRD阴性率：事后分析讲者：Ibrahim Aldoss, MD | City of Hope – Duarte摘要号：6511英文标题：Reduced dose PTCy in patients with acute myeloid leukemia receiving matched unrelated donor allogeneic hematopoietic stem cell transplantation中文标题：减量PTCy用于接受配型无关供者异基因造血干细胞移植的急性髓系白血病患者讲者：Nihar Desai, MD, DM | Princess Margaret Hospital摘要号：6512英文标题：Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial中文标题：COMMANDS研究中luspatercept（LUSPA）对比促红素α（epoetin alfa，EA）治疗未使用促红素治疗的极低、低或中危骨髓增生异常综合征（MDS）患者的总体生存期（OS）与获得输血独立（TI）后反应持续时间分析讲者：Guillermo Garcia-Manero, MD | University of Texas MD Anderson Cancer Center摘要号：6513英文标题：Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study中文标题：bexmarilimab联合阿扎胞苷抑制巨噬细胞检查点Clever-1治疗骨髓增生异常综合征的疗效：BEXMAB Ⅰ/Ⅱ期研究结果讲者：Naval Guastad Daver, MD | Department of Leukemia, The University of Texas MD Anderson Cancer Center摘要号：6514英文标题：Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML中文标题：地西他滨和维奈克拉用于诱导终末分化，以改善TP53突变型MDS和AML的治疗结局讲者：Mendel Goldfinger, MD | Montefiore Einstein Comprehensive Cancer Center摘要号：6515英文标题：IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF)中文标题：IMproveMF更新：imetelstat（IME）联合芦可替尼（RUX）治疗中危1（INT-1）、中危2（INT-2）或高危（HR）骨髓纤维化（MF）患者的Ⅰ/Ⅰb期临床试验讲者：John Mascarenhas, MD | Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai摘要号：6516英文标题：Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial中文标题：asciminib（ASC）治疗接受过1种酪氨酸激酶抑制剂（TKI）治疗的慢性期慢性髓性白血病（CML-CP）患者的疗效和安全性：Ⅱ期ASC2ESCALATE试验的中期分析（IA）讲者：David Jacob Andorsky, MD | Rocky Mountain Cancer Centers, US Oncology Research摘要号：6517英文标题：Age-related macular degeneration in individuals with clonal hematopoiesis中文标题：克隆性造血个体的年龄相关性黄斑变性讲者：Keishla Marie Arce-Ruiz, BS | McGraw/Patterson Center for Population Sciences, Dana-Farber Cancer Institute淋巴瘤与慢性淋巴细胞白血病当地时间：5月31日08:00-09:30报告地点：E450a摘要号：7009英文标题：Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D中文标题：zanubrutinib（zanu）联合维奈克拉（ven）治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）：SEQUOIA研究D组结果讲者：Mazyar Shadman, MD, MPH | Fred Hutchinson Cancer Center and University of Washington摘要号：7010英文标题：Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders中文标题：DZD8586 在经共价或非共价 BTK 抑制剂及 BTK 降解剂治疗后的 CLL/SLL 患者中的I/II期研究讲者：李建勇（江苏省人民医院）摘要号：7011英文标题：SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)中文标题：SEQUOIA研究5年随访，C组：前线zanubrutinib单药治疗del(17p)及未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者讲者：Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS | Alfred Hospital and Monash University摘要号：7012英文标题：A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma中文标题：一项1/2期研究：评估选择性 EZH2 抑制剂 XNW5004 在复发/难治性非霍奇金淋巴瘤患者中的安全性与有效性讲者：邱录贵[中国医学科学院血液病医院（中国医学科学院血液学研究所）]摘要号：7013英文标题：CD79b-targeted antibody-drug conjugate (ADC) SHR-A1912 in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): Data from a phase 1b/2 study中文标题：以 CD79b 为靶点的抗体偶联药物（ADC）SHR - A1912 联合R - GemOx方案用于复发 / 难治性（R/R）弥漫性大 B 细胞淋巴瘤（DLBCL）患者的1b/2期研究数据讲者：李亚军（湖南省肿瘤医院）摘要号：7014英文标题：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): Interim results from the phase II MorningSun study中文标题：固定疗程皮下（SC）莫妥珠单抗（Mosun）治疗既往未治疗的高肿瘤负担滤泡性淋巴瘤（FL）患者：Ⅱ期MorningSun研究的中期结果讲者：Ian W. Flinn, MD, PhD | Tennessee Oncology and OneOncology摘要号：7015英文标题：Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO中文标题：格菲妥单抗联合吉西他滨和奥沙利铂（Glofit-GemOx）治疗复发/难治性（R/R）弥漫大B细胞淋巴瘤（DLBCL）患者：STARGLO研究2年随访结果讲者：Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center摘要号：7016英文标题：Worldwide experience of chronic active EBV infection: Retrospective cohort study中文标题：全球慢性活动性EBV感染经验：回顾性队列研究讲者：王欣然（华中科技大学同济医学院附属同济医院）摘要号：7017英文标题：Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study中文标题：伊布替尼联合维奈克拉一线治疗年龄较大或存在TP53突变的套细胞淋巴瘤（MCL）患者的疗效和安全性：SYMPATICO研究讲者：Michael Wang, MD | Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center创新性治疗—免疫疗法当地时间：6月1日11:15-12:45报告地点：S406摘要号：2514英文标题：Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL)中文标题：靶向CCR8抗体治疗复发/难治性皮肤T细胞淋巴瘤（R/R CTCL）的Ⅰ期临床试验剂量递增阶段初步结果讲者：李志铭（中山大学肿瘤防治中心）浆细胞病当地时间：6月2日08:00-09:30报告地点：E450b摘要号：7509英文标题：Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial中文标题：艾沙妥昔单抗、卡非佐米、来那度胺和地塞米松（Isa-KRd）治疗高危（HR）新诊断多发性骨髓瘤（NDMM）：GMMG-CONCEPT研究中适合移植（TE）患者全队列的首次报告讲者：Lisa B. Leypoldt, MD | University Medical Center Hamburg-Eppendorf摘要号：7510英文标题：Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合硼替佐米（BTZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的首次结果讲者：Xavier P. Leleu, MD, PhD | Hematology, CIC 1082, U1313, CHU, University摘要号：7511英文标题：Heterogeneity in the expression of GPRC5D between patients with multiple myeloma中文标题：多发性骨髓瘤患者中GPRC5D表达的异质性讲者：Harsh Parmar | John Theurer Cancer Center, Hackensack University Medical Center摘要号：7512英文标题：Belantamab mafodotin plus lenalidomide/dexamethasone in newly diagnosed intermediate-fit & frail multiple myeloma patients: Long-term efficacy and safety from the phase 1/2 BELARD clinical trial中文标题：Belantamab mafodotin联合来那度胺/地塞米松治疗新诊断的中度fit和虚弱多发性骨髓瘤患者：来自Ⅰ/Ⅱ期BELARD临床试验的长期疗效和安全性结果讲者：Evangelos Terpos, MD, PhD | Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine摘要号：7513英文标题：Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial中文标题：Linvoseltamab（LINVO）联合卡非佐米（CFZ）治疗复发/难治性多发性骨髓瘤（RRMM）患者：LINKER-MM2研究的初步结果讲者：Salomon Manier, MD, PhD | Hematology Department, Lille University Hospital摘要号：7514英文标题：Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results中文标题：ISB 2001的Ⅰ期首次人体研究：一种针对BCMAxCD38xCD3的三特异性抗体治疗复发/难治性多发性骨髓瘤（RRMM）患者——剂量递增（DE）结果讲者：Eben I. Lichtman, MD | UNC Lineberger Comprehensive Cancer Center摘要号：7515英文标题：Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial中文标题：belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺、硼替佐米和地塞米松（PVd）治疗复发/难治性多发性骨髓瘤（RRMM）患者的微小残留病（MRD）阴性率比较：来自DREAMM-8研究的分析讲者：Suzanne Trudel, MD | Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre摘要号：7516英文标题：Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study中文标题：达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松（DVRd）治疗新诊断多发性骨髓瘤（NDMM）患者：Ⅲ期CEPHEUS研究中不适合移植（TIE）患者的亚组分析讲者：Saad Z Usmani, MD, MBA, FRCP, FASCO | Memorial Sloan Kettering Cancer Center（来源：《肿瘤瞭望》编辑部）声 明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

▎药明康德内容团队编辑 本期看点 1. γ9δ2 T细胞激活剂ICT01联用阿扎胞苷和维奈托克治疗新确诊的老年和/或不适合标准治疗的急性髓系白血病（AML）患者，总完全缓解（CR）率达75%。 2. 治疗实体瘤软脑膜转移（LM）的放射治疗药物Rhenium（186Re）obisbemeda与标准的外照射放疗相比，可使中枢神经系统（CNS）蛛网膜下腔吸收的辐射剂量提高多达8倍。 3. 细胞疗法TED-A9在治疗帕金森病的1/2a期临床试验中表现亮眼，高剂量组所有3名患者的步态冻结症状完全消失。 药明康德内容团队整理 ICT01：公布1/2a期临床试验数据 ImCheck Therapeutics公司公布了其新型γ9δ2 T细胞激活剂ICT01联用阿扎胞苷和维奈托克治疗新确诊的老年和/或不适合标准治疗的AML患者的积极1/2a期临床试验数据。γ9δ2 T细胞是先天免疫系统的一部分，负责对肿瘤和感染的免疫监察。ICT01是一款靶向嗜乳脂蛋白家族成员BTN3A的单克隆抗体疗法，通过与BTN3A结合，它可以选择性地激活γ9δ2 T细胞，并且促进它们迁移和浸润肿瘤，进一步激发CD8阳性T细胞和自然杀伤细胞的抗肿瘤反应。 截至2024年7月19日的数据，16名疗效可评估患者的中位随访时间为4.0个月（范围0.7-7.4个月），总CR率为75%，CR/伴有血液学不完全恢复的完全缓解（CRi）率为94%。第1、2、3和4个治疗周期结束时达到CR/CRi的患者比例分别为44%、81%、88%和94%。总体而言，缓解持续时间为2.5个月，截至数据截止日期患者仍然在持续缓解。中位总生存期数据尚未成熟。 Rhenium（186Re）obisbemeda：公布1期临床试验的中期数据 Plus Therapeutics公司公布了其主打放射治疗药物Rhenium（186Re）obisbemeda治疗实体瘤软脑膜转移的临床试验ReSPECT-LM的最新数据。该疗法是一款新型可注射放疗药物，专门配制用于以安全、有效和方便的方式在CNS肿瘤中递送专一靶向的高剂量辐射，以优化患者临床结局。由于186Re的半衰期短，具有破坏癌组织的β放射能和可用于活体成像的γ放射能，是CNS治疗应用的理想放射性同位素。 20名患者接受了治疗，包括9名原发癌症为乳腺癌的患者，5名原发癌症为非小细胞肺癌的患者，以及6名原发癌症为其他癌症的患者。此次公布的结果显示，治疗后112天时，93%（14/15）患者的脑脊液循环肿瘤细胞（CTC）显示有缓解，包括1例CR和1例疾病稳定（SD）。磁共振成像（MRI）结果显示，75%（12/16）的患者获得缓解或SD，包括5例缓解和7例SD。临床应答结果显示，86%（12/14）的患者获得缓解或SD，包括2例部分缓解（PR）和10例SD。队列1-4组患者的中位总生存期为9个月，16名患者中有6人在分析时仍存活。此外，有3名患者在“同情使用”项目下接受了3次给药，这3名患者的生存时间均超过400天，其中1名患者甚至超过了30个月。新闻稿还指出，与标准的外照射放疗相比，该治疗方法可使CNS蛛网膜下腔吸收的辐射剂量提高多达8倍。 TED-A9：公布1/2a期临床的新试验数据 S.BIOMEDICS公司宣布了其细胞疗法TED-A9在治疗帕金森病的1/2a期临床试验中的首批6名受试者的1年随访数据。TED-A9是一款通过对人类胚胎干细胞（hESC）进行小分子化合物处理而生成的高度纯化中脑多巴胺能祖细胞。通过外科手术，hESC衍生的多巴胺能祖细胞被移植到患者双侧壳核的前、中、后部。移植后，这些细胞将成熟为多巴胺能神经元，通过增强帕金森病患者的神经连接，有望恢复患者的运动功能。 此次公布的结果显示，根据Hoehn和Yahr量表，低剂量组（n=3）患者的运动症状平均改善了19.4%，而高剂量组（n=3）改善了44.4%，表明疾病状态从严重转向较轻。步态冻结（帕金森病患者常见的运动症状之一）在低剂量组的部分患者（1/2）中完全消失，在高剂量组的所有患者（3/3）中完全消失。神经影像技术结果显示，由移植细胞形成的突触中多巴胺转运蛋白（DAT）增加，高剂量组更为明显。安全性方面，没有观察到与移植细胞相关的问题。 INB-200：公布1期临床试验的新数据 IN8bio公司公布其耐化疗的转基因自体γδ T细胞疗法INB-200加入到胶质母细胞瘤患者的替莫唑胺（TMZ）维持治疗中的1期临床试验数据。INB-200是一种强大的协同治疗方法，能在患者接受化疗时持续存在，并保持其识别和杀死癌细胞的能力。 此次公布的结果显示，92%接受INB-200协同治疗的可评估患者的无进展生存期（PFS）超过了接受标准治疗（Stupp方案）患者的中位PFS（6.9个月），大多数患者的PFS超过了基于年龄和肿瘤MGMT状态预测的PFS。此外，5名患者仍然存活，3名患者已返回工作岗位，其中1名患者在治疗后40.5个月时疾病仍然没有进展。活检结果显示，两名患者在接受INB-200治疗后，脑肿瘤微环境中持续存在着γδ T细胞以及CD3阳性和CD8阳性T细胞。 安全性方面，任何队列中均未报告与治疗相关的严重不良事件、剂量限制性毒性（DLT）、细胞因子释放综合征（CRS）、输注反应或免疫效应细胞相关神经毒性（ICAN）。最常见的治疗相关不良事件是1-2级毒性，包括与标准护理TMZ相关的白细胞和血小板计数下降。 SCG101：公布1期临床试验数据 星汉德生物（SCG Cell Therapy）公布了其自主研发的乙型肝炎病毒（HBV）特异性T细胞受体（TCR）-T细胞疗法SCG101的1期临床试验的新数据。SCG101是一种靶向乙型肝炎病毒表面抗原（HBsAg）的特异性自体TCR-T细胞疗法。星汉德生物依托自主研发的独有GianT技术平台，筛选高亲力且高活性的天然TCR，可以有效靶向实体肿瘤中通过主要组织相容性复合体（MHC）表达的细胞内抗原。临床前和临床研究数据显示，SCG101具有肿瘤抑制和HBV共价闭合环状DNA（cccDNA）根除作用，可实现抗肿瘤和抗病毒功能。 此次公布的结果显示，SCG101在晚期HBV相关肝细胞癌（HCC）患者中显示出有希望的抗病毒活性。在接受单次静脉注射5.0×10^7-1.0×10^8个TCR-T细胞/kg剂量的SCG101治疗的12名患者中，所有患者的血清HBsAg水平均显著下降，其中11名患者（92%）的HBsAg水平下降了1.0-4.6 log10，并且在整个长达一年的随访期间，这些患者的HBsAg水平保持在100 IU/mL以下。值得注意的是，有4名患者（33%）在接受单次SCG101输注后的21天内实现了HBsAg的消失，并且这种状态持续了一整个随访期。SCG101的安全性总体上良好，治疗耐受性良好。最常见的治疗相关不良事件包括暂时性的肝酶升高、发热、细胞减少症、CRS、低白蛋白血症和低钠血症。 HL192（ATH-399A）：公布1期临床试验数据 HanAll Biopharma公司、Daewoong Pharmaceutical公司和NurrOn Pharmaceuticals公司成功完成了HL192（ATH-399A）的1期研究。HL192（ATH-399A）是一种用于治疗帕金森病的Nurr1激活剂，此前已在健康受试者中完成了一项1期研究。此次公布的结果显示，该研究在5个不同的剂量组中达到了安全性和耐受性的主要终点，表明在治疗这种使人衰弱的神经系统疾病方面迈出了有意义的一步。HL192（ATH-399A）的耐受性良好，76名受试者均无重大安全问题。接受治疗的患者与接受安慰剂的患者在治疗伴发不良事件上的发生率相当，没有明确的剂量依赖性趋势。药代动力学结果支持每天一次的给药方案。 MaaT033：公布1b期临床试验数据 MaaT Pharma公司宣布，其评估MaaT033在肌萎缩侧索硬化（ALS）患者中疗效的1b期临床试验IASO已达到主要终点。ALS患者连续服用MaaT033两个月后显示出良好的安全性和耐受性。初步的微生物组分析证实了MaaT033已成功移植，进一步支持了其安全性和耐受性结果。 MaaT033是一种源自供体、高浓度、高多样性的口腔微生物群生态系统疗法（Microbiome Ecosystem Therapy），目前正作为一种辅助疗法进行开发，以提高接受造血干细胞移植（HSCT）和其他细胞疗法的患者的总生存率。此前，MaaT033已被欧洲药品管理局（EMA）授予孤儿药资格。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放 参考资料（可上下滑动查看） [1] Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients. Retrieved November 29, 2024, from https://immixbio.com/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-of-hematology-ash-annual-meeting-in-16-relapsed-refractory-al-amyloidosis-patients/ [2] IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting. Retrieved November 29, 2024, from https://investors.in8bio.com/news-releases/news-release-details/in8bio-reports-continued-durable-remissions-phase-1-trial-inb [3] S.BIOMEDICS Investigational Cell Therapy for Parkinson’s Disease With TED-A9 Shows Positive Data at 12-months in Phase 1/2a Clinical Trial. Retrieved November 29, 2024, from https://www.businesswire.com/news/home/20241126606645/en/S.BIOMEDICS-Investigational-Cell-Therapy-for-Parkinson%E2%80%99s-Disease-With-TED-A9-Shows-Positive-Data-at-12-months-in-Phase-12a-Clinical-Trial [4] SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/scg-cell-therapy-presents-promising-phase-1-data-for-a-novel-hbv-specific-tcr-t-therapy-scg101-at-the-aasld-liver-meeting-2024-302314896.html [5] Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference. Retrieved November 29, 2024, from https://www.globenewswire.com/news-release/2024/11/25/2986577/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-SNO-Annual-Conference.html [6] 2876 ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction. Retrieved November 29, 2024, from https://ash.confex.com/ash/2024/webprogram/Paper193493.html [7] HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-announce-successful-completion-of-a-first-in-human-study-for-potential-disease-modifying-therapy-for-parkinsons-disease-302315158.html [8] MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS). Retrieved November 29, 2024, from https://www.businesswire.com/news/home/20241125058999/en/MaaT-Pharma-Announces-Positive-Phase-1b-Results-Meeting-Primary-Endpoint-in-the-Evaluation-of-MaaT033-in-Amyotrophic-Lateral-Sclerosis-ALS/ [9] Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial. Retrieved November 29, 2024, from https://www.accesswire.com/945940/hemogenyx-pharmaceuticals-plc-announces-irb-approval-for-phase-i-clinical-trial [10] GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/gc-biopharma-and-novel-pharma-first-patient-dosed-in-global-phase-i-clinical-trial-for-mps-iiia-treatment-302315952.html [11] Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV. Retrieved November 29, 2024, from https://www.prnewswire.com/news-releases/avirmax-biopharma-announces-first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv-302313714.html [12] uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy. Retrieved November 29, 2024, from https://www.globenewswire.com/news-release/2024/11/21/2985098/0/en/uniQure-Announces-Dosing-of-First-Patient-in-GenTLE-Phase-I-IIa-Clinical-Trial-of-AMT-260-for-the-Treatment-of-Refractory-Mesial-Temporal-Lobe-Epilepsy.html [13] Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. Retrieved November 29, 2024, from https://investors.tenayatherapeutics.com/news-releases/news-release-details/tenaya-therapeutics-doses-first-patient-ridgetm-1-phase-1b [14] Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial. Retrieved November 29, 2024, from https://www.accesswire.com/945940/hemogenyx-pharmaceuticals-plc-announces-irb-approval-for-phase-i-clinical-trial 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。 版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。 分享，点赞，在看，聚焦全球生物医药健康创新